Farr Miller & Washington LLC DC grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 61.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 171,858 shares of the medical instruments supplier’s stock after purchasing an additional 65,265 shares during the period. Becton, Dickinson and makes up about 3.5% of Farr Miller & Washington LLC DC’s portfolio, making the stock its 9th biggest position. Farr Miller & Washington LLC DC owned about 0.06% of Becton, Dickinson and worth $39,988,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the company. Simon Quick Advisors LLC boosted its holdings in shares of Becton, Dickinson and by 1,657.1% during the 3rd quarter. Simon Quick Advisors LLC now owns 123 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 116 shares in the last quarter. Balentine LLC lifted its holdings in Becton, Dickinson and by 45.3% during the 2nd quarter. Balentine LLC now owns 138 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 43 shares during the period. Sun Life Financial INC acquired a new position in Becton, Dickinson and during the 3rd quarter worth about $40,000. Proffitt & Goodson Inc. acquired a new position in Becton, Dickinson and during the 2nd quarter worth about $43,000. Finally, CX Institutional lifted its holdings in Becton, Dickinson and by 80.6% during the 2nd quarter. CX Institutional now owns 186 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 83 shares during the period. Institutional investors own 74.40% of the company’s stock.
In other news, EVP Roland Goette sold 930 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, November 23rd. The shares were sold at an average price of $230.10, for a total transaction of $213,993.00. Following the completion of the transaction, the executive vice president now directly owns 10,085 shares in the company, valued at $2,320,558.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.12% of the stock is currently owned by company insiders.
Several research analysts have commented on the company. Morgan Stanley cut their target price on Becton, Dickinson and from $270.00 to $262.00 and set an “equal weight” rating on the stock in a report on Friday, November 6th. Raymond James dropped their price objective on Becton, Dickinson and from $285.00 to $270.00 and set an “outperform” rating on the stock in a research note on Monday, October 12th. TheStreet downgraded Becton, Dickinson and from a “b” rating to a “c+” rating in a research note on Monday, September 21st. The Goldman Sachs Group raised Becton, Dickinson and from a “buy” rating to a “conviction-buy” rating in a research note on Friday, October 2nd. Finally, UBS Group boosted their price objective on Becton, Dickinson and from $265.00 to $280.00 and gave the company a “neutral” rating in a research note on Monday, August 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Becton, Dickinson and currently has a consensus rating of “Buy” and an average price target of $277.93.
Becton, Dickinson and stock opened at $232.01 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.07 and a debt-to-equity ratio of 0.72. The firm has a 50-day moving average of $236.57 and a 200-day moving average of $244.68. The firm has a market cap of $65.97 billion, a P/E ratio of 83.87, a P/E/G ratio of 2.02 and a beta of 0.83. Becton, Dickinson and Company has a 1-year low of $197.75 and a 1-year high of $286.72.
Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, November 10th. The medical instruments supplier reported $2.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.52 by $0.27. Becton, Dickinson and had a net margin of 5.11% and a return on equity of 13.30%. The company had revenue of $4.78 billion during the quarter, compared to analyst estimates of $4.48 billion. During the same period in the prior year, the business posted $3.31 earnings per share. Becton, Dickinson and’s revenue for the quarter was up 4.4% on a year-over-year basis. Research analysts forecast that Becton, Dickinson and Company will post 12.5 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be issued a dividend of $0.83 per share. This represents a $3.32 annualized dividend and a dividend yield of 1.43%. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Wednesday, December 9th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 30.98%.
Becton, Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: Using other technical indicators with support levels
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.